Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Select Advanced Solid Tumors 1Recurrence 1Pregnancy Related 1Neuroblastoma 1Neoplasms 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Endometrial Neoplasms 1

Interventions

pembrolizumab 46Paclitaxel 42Carboplatin 34Bevacizumab 18Specimen Handling 17Letrozole 16lenvatinib 13Magnetic Resonance Spectroscopy 12dostarlimab 11Cisplatin 11Biopsy 11olaparib 10Taxes 10Fulvestrant 9Doxorubicin 9abemaciclib 8Megestrol Acetate 8Docetaxel 8durvalumab 7atezolizumab 7Nivolumab 7Gemcitabine 7Blood Specimen Collection 7palbociclib 6Oxaliplatin 6Observation 6Fluorouracil 6niraparib 5Tirzepatide 5Surveys and Questionnaires 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Antibodies, Monoclonal × 1 year × Clear all
NCT06366347 2026-02-11

ALPINE: Maintenance Letrozole/Abemaciclib

Dana-Farber Cancer Institute

Phase 2 Recruiting
32 enrolled
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡